Literature DB >> 17261023

Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry.

Jonathan S Kingsbury1, Roger Théberge, John A Karbassi, Amareth Lim, Catherine E Costello, Lawreen Heller Connors.   

Abstract

Wild-type transthyretin (TTR), normally a soluble plasma-circulating protein, can be amyloidogenic, i.e., form tissue-deposited fibrillar material in the extracellular matrix of various organs throughout the body. Senile systemic amyloidosis (SSA) is one such pathology and features TTR-containing amyloid deposits that are found primarily in the heart. The cause for this transition from soluble to insoluble protein in SSA is yet to be determined as specific structural features that might favor TTR fibrillogenesis have not yet been identified. The precise characterization of ex vivo fibril deposits might provide insight, but structural analyses of TTR from amyloid deposits have been hindered thus far by the lack of purification strategies that overcome the insolubility of the tissue-derived protein without degrading it. Consequently, the true biochemical nature of deposited TTR remains in question. In this study, we provide detailed analyses of both the soluble (serum) and deposited (tissue) forms of TTR from cases of SSA. In the serum, a distribution of mixed disulfides, specifically S-sulfonated and S-cysteinylated forms of TTR, as well as the unmodified protein were identified. The relative levels of the three TTR species in the SSA group were comparable to amounts present in sera from age-matched control groups. For characterization of the amyloid deposited TTR, we investigated cardiac tissue samples obtained from three separate cases of SSA. We report a novel chromatographic purification strategy performed under nonreducing conditions (to maintain cysteine disulfide status) and the use of this procedure in conjunction with detailed mass spectrometric analysis of TTR from the amyloid deposits. A series of C-terminal TTR fragments with N-termini ranging from amino acids 46 to 55 were identified. We also determined that the deposits in all samples contained Cys10 disulfide-linkedhomodimers composed of full-length TTR monomers. This last finding suggests an important role for Cys10 conjugation in the transition from soluble TTR to the pathological amyloid fibril.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261023     DOI: 10.1021/ac061546s

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  18 in total

1.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.

Authors:  Elena S Klimtchuk; Tatiana Prokaeva; Nicholas M Frame; Hassan A Abdullahi; Brian Spencer; Surendra Dasari; Haili Cui; John L Berk; Paul J Kurtin; Lawreen H Connors; Olga Gursky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

2.  Top-Down Analysis of Small Plasma Proteins Using an LTQ-Orbitrap. Potential for Mass Spectrometry-Based Clinical Assays for Transthyretin and Hemoglobin.

Authors:  Roger Théberge; Giuseppe Infusini; Weiwei Tong; Mark E McComb; Catherine E Costello
Journal:  Int J Mass Spectrom       Date:  2011-03-01       Impact factor: 1.986

3.  Novel Zn2+-binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition.

Authors:  Leonardo de C Palmieri; Luis Mauricio T R Lima; Juliana B B Freire; Lucas Bleicher; Igor Polikarpov; Fabio C L Almeida; Debora Foguel
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

4.  Detection of high-molecular-weight amyloid serum protein complexes using biological on-line tracer sedimentation.

Authors:  Jonathan S Kingsbury; Thomas M Laue; Susan F Chase; Lawreen H Connors
Journal:  Anal Biochem       Date:  2012-03-27       Impact factor: 3.365

5.  Experimentally derived structural constraints for amyloid fibrils of wild-type transthyretin.

Authors:  David A Bateman; Robert Tycko; Reed B Wickner
Journal:  Biophys J       Date:  2011-11-15       Impact factor: 4.033

6.  Transthyretin variants with improved inhibition of β-amyloid aggregation.

Authors:  Parth Mangrolia; Dennis T Yang; Regina M Murphy
Journal:  Protein Eng Des Sel       Date:  2016-04-19       Impact factor: 1.650

7.  Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.

Authors:  Francesca Lavatelli; David H Perlman; Brian Spencer; Tatiana Prokaeva; Mark E McComb; Roger Théberge; Lawreen H Connors; Vittorio Bellotti; David C Seldin; Giampaolo Merlini; Martha Skinner; Catherine E Costello
Journal:  Mol Cell Proteomics       Date:  2008-05-12       Impact factor: 5.911

8.  Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity.

Authors:  Joel Buxbaum; James Koziol; Lawreen H Connors
Journal:  Amyloid       Date:  2008-12       Impact factor: 7.141

9.  Differential modification of Cys10 alters transthyretin's effect on beta-amyloid aggregation and toxicity.

Authors:  Lin Liu; Jie Hou; Jiali Du; Robert S Chumanov; Qingge Xu; Ying Ge; Jeffrey A Johnson; Regina M Murphy
Journal:  Protein Eng Des Sel       Date:  2009-06-23       Impact factor: 1.650

10.  Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses.

Authors:  Celia M Torres-Arancivia; Deborah Chang; William E Hackett; Joseph Zaia; Lawreen H Connors
Journal:  Biochemistry       Date:  2020-11-03       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.